Roche Holding AG Stock

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange 11:31:22 2024-04-12 EDT 5-day change 1st Jan Change
225 CHF -0.49% Intraday chart for Roche Holding AG +2.51% -7.98%

Financials

Sales 2024 * 59.76B 65.33B 89.96B Sales 2025 * 63.39B 69.29B 95.41B Capitalization 181B 198B 273B
Net income 2024 * 13.29B 14.53B 20B Net income 2025 * 14.67B 16.03B 22.08B EV / Sales 2024 * 3.26 x
Net Debt 2024 * 13.69B 14.96B 20.6B Net Debt 2025 * 7.58B 8.28B 11.4B EV / Sales 2025 * 2.98 x
P/E ratio 2024 *
13.5 x
P/E ratio 2025 *
12.1 x
Employees 103,605
Yield 2024 *
4.26%
Yield 2025 *
4.44%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Roche Holding AG

1 day-0.49%
1 week+2.51%
Current month-2.05%
1 month-8.07%
3 months-10.89%
6 months-10.96%
Current year-7.98%
More quotes
1 week
217.00
Extreme 217
228.90
1 month
217.00
Extreme 217
234.85
Current year
217.00
Extreme 217
255.90
1 year
217.00
Extreme 217
293.55
3 years
217.00
Extreme 217
404.20
5 years
217.00
Extreme 217
404.20
10 years
206.35
Extreme 206.35
404.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 65 95-12-31
More insiders
Date Price Change Volume
24-04-12 225 -0.49% 1,292,148
24-04-11 226.1 +0.76% 1,355,646
24-04-10 224.4 +1.17% 1,052,844
24-04-09 221.8 +0.91% 1,519,720
24-04-08 219.8 +0.14% 1,494,784

Delayed Quote Swiss Exchange, April 12, 2024 at 11:31 am

More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
225 CHF
Average target price
281.3 CHF
Spread / Average Target
+25.01%
Consensus